Publications by authors named "Mark Awad"

Claim this Profile
D
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.
Lingzhi Hong, Alessandro Di Federico, Bolun Liu, Alissa J Cooper, Joao V Alessi, Mark M Awad

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer.
Xinan Wang, Biagio Ricciuti, Arielle Elkrief, Joao V Alessi, Alessandro Di Federico, Mark M Awad

J Immunother Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Mark M Awad

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.
Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, Andrea De Giglio, Francesca Lo Bianco, Mark M Awad

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma.
William Zhao, Thinh T Nguyen, Atharva Bhagwat, Akhil Kumar, Bruno Giotti, Mark Awad

Nat Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRATER tumor niches facilitate CD8 T cell engagement and correspond with immunotherapy success.
Aya Ludin, Georgia L Stirtz, Asaf Tal, Ajit J Nirmal, Kathleen L Pfaff, Mark M Awad

Cell· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer.
Jessica S Ross, Rohit Thummalapalli, Christopher A Febres-Aldana, Daniel Muldoon, Christina Falcon, Mark M Awad

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, Adam A Barsouk, Arianna Pagliaro, Mark M Awad

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment.
James R Lindsay, Jennifer Altreuter, Joao V Alessi, Jason L Weirather, Anita Giobbie-Hurder, Mark M Awad

Cell Rep Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes.
Igor Odintsov, Mark M Hammer, Biagio Ricciuti, Federica Pecci, Mark M Awad

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 and PD-1 Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.
Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder, Bijaya Sharma, Kristen Felt, Mark M Awad

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
Alissa J Cooper, Edoardo Garbo, Andrea Arfe, Michael Conroy, Narek Shaverdian, Mark M Awad

Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.
Federica Pecci, Prashasti Agrawal, Jessica S Ross, Biagio Ricciuti, Seshiru Nakazawa, Mark M Awad

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas.
Jessica S Ross, Rohit Thummalapalli, Kristine Lacuna, Rania G Aly, Marina K Baine, Mark M Awad

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC.
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, Felix H Gottlieb, Francesco Facchinetti, Mark M Awad

J Thorac Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
Patrick M Forde, Jonathan D Spicer, Mariano Provencio, Tetsuya Mitsudomi, Mark M Awad

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas.
Andréanne Gagné, Joao Victor M Alessi, Biagio Ricciuti, Giuseppe Lamberti, Mark M Awad

Lung Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
Biagio Ricciuti, Francesca Fusco, Alissa Cooper, Edoardo Garbo, Federica Pecci, Mark M Awad

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC.
Maliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li, Mark Awad

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Sarcopenia With Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset Validation.
Anurag Saraf, John He, Kee-Young Shin, Jakob Weiss, Mark M Awad

Clin Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients.
Adriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, Teja Ganta, Thomas U Marron, Mark M Awad

Clin Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
Seshiru Nakazawa, Federica Pecci, Igor Odintsov, Dimitris Gazgalis, Felix H Gottlieb, Mark M Awad

Cancer Discov· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
Federica Pecci, Rohit Thummalapalli, Stephanie L Alden, Biagio Ricciuti, Joao V Alessi, Mark M Awad

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report.
Elio Adib, Amin H Nassar, Elias Bou Farhat, Shyam K Tanguturi, Rifaquat M Rahman, Mark M Awad

JTO Clin Res Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Mark M Awad

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis